An observational study in ASCVD, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To construct a comprehensive big data platform for Chinese people with panvascular disease, and establish a Chinese panvascular disease oriented to guide treatment decisions Cohort and imaging, biological database; According to the clinical features, morphological structure, pathological characteristics of panvascularization, vascular age As the core of the evaluation, a standard evaluation system and a risk prediction model of intervention technology suitable for the diagnosis and treatment of patients with panvascular disease in China were established. Into the Further optimize the treatment strategies, protocols and clinical pathways for panvascular disease to improve patient prognosis and promote its application.
3.2 Selection of Research Subjects (1) Inclusion Criteria:
2.1.1 Coronary atherosclerotic heart disease: It includes acute coronary syndrome, stable angina pectoris, moderate to severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.
2.2. Cerebrovascular diseases: □2.2.1 Intracranial atherosclerotic diseases: including ischemic stroke, transient ischemic attack or moderate intracranial artery disease The above is narrow. □2.2.2 Carotid atherosclerotic diseases: including carotid artery disease and vertebral artery disease.
2.3. Aorta: □2.3.1 Atherosclerotic aortic diseases: including severe aortic plaques, aortic ulcers, aortic stenosis or atresia,
Aortic dissection, aortic aneurysm, etc. 2.4. Peripheral Arteries:
Compare the prediction models.
□2.4.1 Atherosclerotic diseases of the upper extremities: including diseases of the subclavian artery, axillary artery, brachial artery and other parts.
The 3rd Edition May 8, 2026 □2.4.3 Mesenteric atherosclerotic disease □2.4.2 Atherosclerotic disease of the renal artery □2.4.4 Atherosclerotic disease of the lower extremity arteries Group B. Patients with a single atherosclerotic vascular disease of the above-mentioned arteries. Group C. People at risk of pan-vascular disease. Have at least one of the following: Abdominal obesity: Waist circumference ≥90cm for men and ≥85cm for women; Fasting blood glucose ≥6.1mmol/L and/or 2-hour postprandial blood glucose ≥7.8mmol/L, and/or diabetes has been diagnosed and treated Healer; Those with blood pressure ≥130/85 MMHG and/or who have been diagnosed with hypertension and are receiving treatment; Those with fasting high-density lipoprotein cholesterol \<1.04mmol/L, and/or those who have been diagnosed with hyperlipidemia and are receiving treatment. 3. The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs each
Informed consent form approved by the ethics committee of the clinical center. (2) Exclusion criteria:
1. Concurrent malignant tumors under treatment (such as during radiotherapy, chemotherapy, surgery, etc.) 2. Concurrent diseases requiring urgent treatment (this item is not excluded after the condition has been stabilized after treatment): such as acute infection, hyperemia Pressure crisis, diabetic ketoacidosis, aortic dissection, etc 3. Currently suffering from severe heart failure (NYHA grade 4) 4. Currently suffering from liver failure (ALT or AST≥ 5 times the upper limit of normal) or current renal failure (any cause of renal function decline (defined as eGFR\<15mL/(min·1.73m2) or currently undergoing dialysis treatment) 5. Women who are pregnant or breastfeeding, or those planning to become pregnant during the research period. 6. Those with severe mental illnesses (except for mild to moderate anxiety and depression) 7. Organ transplantation 8. Expected survival period \<3 years 9. Blood-borne infectious diseases: including HIV infection, AIDS, active hepatitis B, hepatitis C, etc. 10. Any situation in which the researchers consider it unsuitable to participate in the study.
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 16, 2026. See what changed
This is a prospective cohort study with 50,000 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group A: Patients with pan-vascular diseases. This refers to those involving two or more of the following vascular diseases:
Coronary arteries: Coronary atherosclerotic heart disease, including acute coronary syndrome, stable angina pectoris, moderate to severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.
Cerebrovascular diseases: Intracranial atherosclerotic diseases, including ischemic stroke, , or moderate intracranial artery disease.
Cerebrovascular diseases: Carotid atherosclerotic diseases, including carotid artery disease and vertebral artery disease.
Aorta: Atherosclerotic aortic diseases, including severe aortic plaques, aortic ulcers, aortic stenosis or atresia, aortic dissection, aortic aneurysm, etc.
Peripheral arteries: Atherosclerotic diseases of the upper extremities, including diseases of the subclavian artery, axillary artery, brachial artery, and other parts.
Peripheral arteries: Mesenteric atherosclerotic disease.
Peripheral arteries: Atherosclerotic disease of the renal artery.
Peripheral arteries: Atherosclerotic disease of the lower extremity arteries.
Group B: Patients with a single atherosclerotic vascular disease of the above-mentioned arteries.
Group C: People at risk of pan-vascular disease. Must have at least one of the following:
Abdominal obesity: Waist circumference ≥ 90 cm for men and ≥ 85 cm for women.
Fasting blood glucose ≥ 6.1 mmol/L and/or 2-hour postprandial blood glucose ≥ 7.8 mmol/L, and/or diabetes has been diagnosed and treated.
Blood pressure ≥ 130/85 mmHg and/or have been diagnosed with hypertension and are receiving treatment.
Fasting high-density lipoprotein cholesterol \< 1.04 mmol/L, and/or have been diagnosed with hyperlipidemia and are receiving treatment.
-The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs the form approved by the ethics committee of the clinical center.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient had atherosclerosis in 2 or more vessels
Other: no different intervention between the two cohort.
The patient had atherosclerosis in 1 vessel
individuals at high risk of ASCVD or suffering from metabolic syndrome
no different intervention between the two cohort.
Cardiovascular adverse events
Time frame: 1, 3, and 5 years follow-up
Cardiovascular mortality
Time frame: 1, 3, and 5 years follow-up
Rate of receiving vascular revascularization
Time frame: 1, 3, and 5 years follow-up
Readmission rate for vascular reasons
Time frame: 1, 3, and 5 years follow-up
Not enrolling at this site.
Not enrolling at this site.
Started Feb 2024 (actual). Primary completion is estimated for Nov 2028, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →